Welcome Dr. Shayna Sarosiek!
We are pleased to announce the addition of Dr. Shayna Sarosiek to the Bing Center for Waldenstrom's Macroglobulinemia.
Prior to joining the Bing Center, Dr. Sarosiek completed her Internal Medicine residency, as well as her Amyloidosis and Hematology/Oncology Fellowship at Boston University Medical Center. After completing her training she remained as a faculty member at Boston University for 4 years. During that time she worked as a hematologist treating patients with benign and malignant hematologic issues, such as monoclonal gammopathy of undetermined significance (MGUS), lymphoma, WM, and multiple myeloma. She focused the majority of her research efforts on plasma cell disorders, including MGUS, multiple myeloma and amyloidosis. She also actively participated in the care of patients at the Boston University Amyloidosis Center and has published many original research articles in that field. She is looking forward to using the expertise she gained at that center to improve the care of patients with WM and AL amyloidosis.
In the Bing Center Dr. Sarosiek will be joining Dr. Jorge Castillo in the clinic to see patients and help care for the constantly increasing number of Waldenstrom patients at our center. She will also be actively involved in clinical research and will focus her research efforts on the use of immunotherapies and antibody treatments in WM, as well as developing therapies and caring for those patients who have both WM and AL amyloidosis.
Please join us in welcoming Dr. Sarosiek to the Bing Center!
Waldenstrom's Macroglobulinemia Clinic
The Waldenstrom's Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
For more information on the WM Clinic at DFCI, please visit the DFCI Center for Hematologic-Oncology/Waldenstrom's Macroglobulinemia Clinic.
Basic Research
Waldenström’s macroglobulinemia (WM) is a distinct B-cell malignancythat results from the accumulation, predominantly in the bone marrow, of clonally related B type lymphocytes, lymphoplasmacytic cells and plasma cells which secrete a monoclonal IgM protein.1 This condition is considered to correspond to the lymphoplasmacytic lymphoma (LPL) as defined by the World Health Organization classification system.2 Most cases of LPL are WM, with less than 5% of cases made up of IgA, IgG and non-secreting LPL ...
Latest Bing Center News
Advances in Multiple Myeloma and Waldenstrom’s Macroglobulinemia including COVID-19 Update
Please join the Center for Multiple Myeloma for a free webinar for patients and families to learn about the most recent updates in muliple myeloma and Waldenstrom's macroglobulinemia including the impact of COVID-19 and vaccination.
The first issue of the 22nd volume of the IWMF Torch is now online!
Greetings to the entire WM community worldwide! Happy to have 2020 behind us, we now focus on COVID vaccines being widely available early in 2021. We all look forward eventually to being able to visit with our loved ones and share good times again.
Waldenstrom Macroglobulinemia Patient Story: 17-Year Survivor
When Peter DeNardis was diagnosed with Waldenstrom macroglobulinemia 17 years ago, he had no idea what his next steps would be. Follow along to hear the story of his diagnosis, treatment journey and where he is now, including all of the “peaks and valleys” that come along with navigating cancer. He also shares personal advice for those who are newly diagnosed with Waldenstrom macroglobulinemia.
New Treatment Options for Waldenstrom Macroglobulinemia - ASH 2020 Report
Can New Drug Combinations Bring More Effective Treatment Options? New combination drug regimens are being studied for the treatment of Waldenstrom macroglobulinemia (WM). In this segment, Dr. Jorge Castillo, MD, of Dana-Farber Cancer Institute updates patients on the information presented at the recent American Society of Hematology (ASH) conference and suggests that Waldenstrom patients pay attention to the combination of ibrutinib and rituximab (INNOVATE Study), that have shown faster and deeper responses over time versus rituximab alone.
#finishSTRONG Challenge - Dr. Edward Laane, Running for Waldenstroms!
Dr. Edward Laane has completed his 3 events in the 2020 B.A.A. Virtual #finishSTRONG Challenge! His official times for the 5K, 10K, and Half Marathon are listed below.
North America SGL Check-in Call with Drs Jorge Castillo & Shayna Sarosiek (Recorded Zoom Call)
Operational roles & functions of the Bing Center, as well as general WM questions regarding the current Pfizer, Moderna and AstraZeneca COVID-19 Vaccines. Also an update from the latest ASH conference. Recorded December 9, 2020.
Ibrutinib Plus Rituximab Data Surprising in Waldenstrom’s Macroglobulinemia
Christian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.
Bing Neel Support Group Meeting - 11/22/2020 - Video
Thank you so much for your interest in our recent Bing-Neel Syndrome support group meeting. Many of you were able to join the Zoom meeting live, while others volunteered to watch the recorded Zoom video [https://youtu.be/XQoqKzMshSI]. Many thanks to all who helped make this possible (the doctors, the IWMF office, The Bing Center for WM, the local support group members who helped plan, and all of you for your patience with me in pulling this together).
Addressing Unmet Needs in WM (Webcast)
With a focus on the latest clinical trial data supporting individualized treatment strategies, this accredited, on-demand activity discusses best practices for addressing unmet needs in treatment selection, sequencing, and disease monitoring in Waldenström macroglobulinemia (WM).
Great Debates in Hematological Malignancies - 2021
We're pleased to announce that registration is now open for the 2021 Great Debates & Updates Conferences. Each meeting will cover the most critical updates occurring in the field, while incorporating a distinct focus on the latest advances and treatment options.